Drawing for GAMBRO

USPTO serial 75892982

GAMBRO

Reviewed by CopyMark Law Group

Reg. 2553625Status 710
Filing date
Status date
Registration date
Mar 26, 2002
Examiner
KEAM, ALEX S
Law office
GENERIC WEB UPDATE

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with GAMBRO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey C. Nichols

One Baxter ParkwayDeerfield, IL 60015UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005PHARMACEUTICAL AND HYGIENIC PREPARATIONS FOR MEDICAL PURPOSE, NAMELY FOR THE TREATMENT OF RENAL DISEASES AND BLOOD TREATMENT; DIETETIC SUBSTANCES ADAPTED FOR MEDICAL USE, NAMELY, DIETARY SUPPLEMENTS FOR THE TREATMENT OF KIDNEY DISEASES; CONSUMABLE PRODUCTS, NAMELY PLASTER, SURGICAL DRESSINGS AND DISINFECTANTS FOR MEDICAL PURPOSE, NAMELY DIALYSIS AND APHERESIS, CONCENTRATES IN SOLID OR LIQUID FORM FOR PREPARING DIALYSIS FLUID AND OTHER FLUIDS INTENDED FOR MEDICAL TREATMENT, NAMELY, DIALYSIS FLUID FOR HEMODIALYSIS, REPLACEMENT FLUID FOR HEMOFILTRATION OR HEMODIAFILTRATION, DISINFECTION SOLUTIONS, CLEANSING SOLUTIONS, DECALCIFYING SOLUTIONS, DIALYSIS FLUID FOR PERITONEAL DIALYSIS; SOLUTIONS FOR USE IN BLOOD COMPONENT TECHNOLOGY, NAMELY, ANTICOAGULANT, ADDITIVE, RECONSTITUTING, CELL STORAGE AND TREATMENT SOLUTIONS, BLOOD COMPONENTS, NAMELY, ERYTHROCYTES, LEUKOCYTES, THROMBOCYTES, STEM CELLS AND BLOOD PLASMASECTION 8 - CANCELLEDMar 8, 2000

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 7, 2022CAEXCANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Mar 26, 2021REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Feb 10, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 10, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 10, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Feb 10, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 10, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 10, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 20, 2012NA89NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Feb 19, 2012RNL1REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Feb 19, 201289AGREGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTEDThe USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary.
Feb 13, 2012E89RTEAS SECTION 8 & 9 RECEIVED
Jan 4, 2012ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Sep 17, 2008ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 17, 2008REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 4, 2007C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Sep 6, 2007815FREGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
Sep 6, 2007E815TEAS SECTION 8 & 15 RECEIVED
May 18, 2007CFITCASE FILE IN TICRS
Mar 26, 2002R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 3, 2001CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Oct 2, 2001DOCKASSIGNED TO EXAMINER
Sep 27, 2001SUPCSTATEMENT OF USE PROCESSING COMPLETE
Sep 19, 2001IUAFUSE AMENDMENT FILED
Apr 24, 2001NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 30, 2001PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 29, 2000NPUBNOTICE OF PUBLICATION
Nov 24, 2000CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Aug 14, 2000CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 14, 2000CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 8, 2000DOCKASSIGNED TO EXAMINER
Jun 6, 2000DOCKASSIGNED TO EXAMINER
Jun 2, 2000DOCKASSIGNED TO EXAMINER

Frequently asked questions

Related guidance